References - AMD Future Perspectives: New promising drugs


3. Singerman LJ WA, Sallstig P. OSPREY trial: randomized, active-controlled, phase II study to evaluate safety and efficacy of RTH258, a humanized single-chain anti-VEGF antibody fragment, in patients with neovascular AMD. Association for Research in Vision and Ophthalmology Annual Meeting; May 3-7, 2015; Denver, CO.


25. Regeneron Announces Phase 2 Study of Aflibercept Co-Formulated with Rinucumab (anti-PDGF-
beta) Shows No Benefit Over Aflibercept Alone in Neovascular Age-Related Macular Degeneration.

26. T. J. A phase 1 study of oral tyrosine kinase inhibitor (X-82) in previously treated wet age-related macular degeneration. 15th EURETINA Congress; 17-20/09/2015; Nice, France 2015.


34. Brown DM. Phase 1 study of combination therapy with nesvacumab and aflibercept for neovascular AMD and diabetic macular edema. AAO Annual Meeting; October 2016; Chicago, IL 2016.


